Skip to content
  • Home
  • News & Events
  • Careers
  • Resources
    • Azurity Code of Conduct
    • Azurity Solutions
    • Azurity Solutions – Patient Direct
    • E-Z Rx®
    • Patient Support
    • Compliance
    • Medical Information
    • Patents & Trademarks
  • Contact Us
Azurity Pharmaceuticals
  • Company
    • About Us
    • Management Team
    • Board of Directors
  • Products
    • Products
    • Anti-Infective
      • FIRVANQ®
    • Cardiovascular/Cardiology
      • BiDil®
      • EDARBI®
      • EDARBYCLOR®
      • EPANED®
      • KATERZIA®
      • QBRELIS®
      • SOTYLIZE®
    • Central Nervous System/Cerebrovascular
      • EPRONTIA®
      • EVEKEO®
      • EVEKEO ODT®
      • FLEQSUVY®
      • HORIZANT®
      • NYMALIZE®
      • ZENZEDI®
      • ZONISADE®
    • Endocrinology
      • ADTHYZA®
      • TRIPTODUR®
    • Gastrointestinal
      • KONVOMEP®
    • Oncology
      • GLIADEL® Wafer
      • XATMEP®
    • Certain products listed may be owned by a subsidiary of Azurity Pharmaceuticals.
  • Pipeline
  • Compounding Kits
    • Compounding Kits
    • FIRST® – Omeprazole
    • FIRST® – Pantoprazole
    • FIRST® – Lansoprazole
    • FIRST® – BLM Mouthwash
    • FIRST® – Metronidazole
    • FIRST® – Progesterone
Select Page

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent Posts

  • Azurity Pharmaceuticals Acquires Slayback Pharma
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension)
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
  • Azurity Pharmaceuticals Announces Richard Blackburn as New CEO

Recent Comments

    Archives

    • September 2023
    • October 2022
    • September 2022
    • July 2022
    • February 2022
    • November 2021
    • September 2021
    • August 2021
    • February 2021
    • August 2020
    • July 2019
    • June 2019
    • April 2018
    • March 2018
    • January 2018

    Categories

    • CutisPharma Press Releases
    • Legacy Arbor Archives
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Home

    Pipeline

    Contact Us

    Company

    • About Us
    • Management Team
    • Board of Directors
    • Follow

    Products

    • ADTHYZA®
    • BIDIL®
    • EDARBI®
    • EDARBYCLOR®
    • EPANED®
    • EPRONTIA®
    • EVEKEO®
    • EVEKEO ODT®
    • FIRVANQ®
    • FLEQSUVY®
    • GLIADEL® Wafer
    • HORIZANT®
    • KATERZIA®
    • KONVOMEP®
    • NYMALIZE®
    • QBRELIS®
    • SOTYLIZE®
    • TRIPTODUR®
    • XATMEP®
    • ZENZEDI®
    • ZONISADE®

    Compounding Kits

    • FIRST® – Omeprazole
    • FIRST® – Pantoprazole
    • FIRST® – Lansoprazole
    • FIRST® – BLM Mouthwash
    • FIRST® – Metronidazole
    • FIRST® – Progesterone

    Resources

    • Azurity Code of Conduct
    • Azurity Solutions
    • Azurity Solutions – Patient Direct
    • E-Z Rx®
    • Patient Support
    • Compliance
    • Medical Information
    • Patents & Trademarks
    • Terms of Use
    • Privacy Policy and Cookie Notice
    • Web Accessibility Policy

    Product labeling, packaging, and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates. The Information contained herein, including product information, is intended only for residents of the United States.

    © 2019 – 2023 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. PP-AZ-US-0024
    AZ_Logo_White
    ADA Site Compliance-Accessibility Policy

    Sign Up for Email Updates

    Share your email to receive information about AZURITY® and new hypothyroidism resources.

    *Fields are required

    Terms and conditions

    By clicking Submit, you agree to receive product and disease state information from Azurity

    All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

    I accept(Required)

    †Terms and Conditions must be accepted before submission.

    Learn More About AZURITY®

    Learn more about how AZURITY may benefit your patients.

    *Fields are required.

    Terms and conditions

    By clicking Submit, you agree to receive product and disease state information from Azurity Pharmaceuticals, Inc. All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

    I Accept(Required)

    †Terms and Conditions must be accepted before submission.